Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Yanjie Niu

Combination of Chemotherapy and Gefitinib as First-Line Treatment for Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: A Randomized Controlled Trial

International Journal of Cancer

Cancer Research

Oncology

2017

English

Related publications

P3.13-24 Efficacy of EGFR-TKIs Compared With Chemotherapy as First-Line Therapy in Patients With EGFR Rare Mutation Advanced Lung Adenocarcinoma

Journal of Thoracic Oncology

English

Phase II Trial of Gefitinib in Combination With Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer With Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001

Journal of Thoracic Oncology

English

140PD: LUX-Lung 7: A Phase IIb, Global, Randomised, Open-Label Trial of Afatinib vs Gefitinib as First-Line Treatment for Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC) Harbouring Activating EGFR Mutations

Journal of Thoracic Oncology

English

Pemetrexed Had Significantly Better Clinical Efficacy in Patients With Stage IV Lung Adenocarcinoma With Susceptible EGFR Mutations Receiving Platinum-Based Chemotherapy After Developing Resistance to the First-Line Gefitinib Treatment

OncoTargets and Therapy

Oncology

Pharmacology

2016

English

Central Nervous System Progression in Advanced Non–small Cell Lung Cancer Patients With EGFR Mutations in Response to First-Line Treatment With Two EGFR-TKIs, Gefitinib and Erlotinib: A Comparative Study

English

Chemotherapy Combined With Bevacizumab for the Treatment of Advanced Lung Adenocarcinoma Cancer Harboring EGFR‐ANXA2, EGFR‐RAD51, ATR and BRCA2 Mutations: A Case Report

English

IFCT-0401 Trial: A Phase II Study of Gefitinib Administered as First-Line Treatment in Advanced Adenocarcinoma With Bronchioloalveolar Carcinoma Subtype

Journal of Thoracic Oncology

English

Brief Report: Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced Non–Small-Cell Lung Cancer With Sensitizing EGFR Mutation

Journal of Thoracic Oncology

English

Real-World Experience of Afatinib as a First-Line Therapy for Advanced EGFR Mutation-Positive Lung Adenocarcinoma

Oncotarget

Oncology

2017

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Yanjie Niu

Combination of Chemotherapy and Gefitinib as First-Line Treatment for Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: A Randomized Controlled Trial

Related publications

P3.13-24 Efficacy of EGFR-TKIs Compared With Chemotherapy as First-Line Therapy in Patients With EGFR Rare Mutation Advanced Lung Adenocarcinoma

Phase II Trial of Gefitinib in Combination With Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer With Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001

140PD: LUX-Lung 7: A Phase IIb, Global, Randomised, Open-Label Trial of Afatinib vs Gefitinib as First-Line Treatment for Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC) Harbouring Activating EGFR Mutations

Pemetrexed Had Significantly Better Clinical Efficacy in Patients With Stage IV Lung Adenocarcinoma With Susceptible EGFR Mutations Receiving Platinum-Based Chemotherapy After Developing Resistance to the First-Line Gefitinib Treatment

Central Nervous System Progression in Advanced Non–small Cell Lung Cancer Patients With EGFR Mutations in Response to First-Line Treatment With Two EGFR-TKIs, Gefitinib and Erlotinib: A Comparative Study

Chemotherapy Combined With Bevacizumab for the Treatment of Advanced Lung Adenocarcinoma Cancer Harboring EGFR‐ANXA2, EGFR‐RAD51, ATR and BRCA2 Mutations: A Case Report

IFCT-0401 Trial: A Phase II Study of Gefitinib Administered as First-Line Treatment in Advanced Adenocarcinoma With Bronchioloalveolar Carcinoma Subtype

Brief Report: Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced Non–Small-Cell Lung Cancer With Sensitizing EGFR Mutation

Real-World Experience of Afatinib as a First-Line Therapy for Advanced EGFR Mutation-Positive Lung Adenocarcinoma